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Background: We hypothesized worsening of AR post TAVI may be more detri-
mental on survival than the severity of AR alone.
Methods: The CoreValve ANZ Study is currently enrolling patients with AS at 10
centers in Australia and New Zealand. AR was reported as none (N), trace (Tr), mild
(Mild), moderate (Mod), severe (Sev). N/Tr AR patients were combined since TAVI
studies commonly report them together. Mod/Sev patients were combined due to
small samples. We assessed change in AR comparing discharge with baseline echo,
and grouped patients as Unchanged/Improved (UC/Imp-AR) or Worsened (Worse-
AR). Primary endpoint was all-cause mortality at 2 years.
Results: Overall baseline characteristics include; mean age of 846 years, 55.4%male,
a mean logistic EuroSCORE 17%10.8%, STS risk of 5.84.0%, mean AVA 0.7 cm2;
mean gradient 50.8  15.4 mmHg, and mean LVEF 58.3%12.0%. Patients with
Worse-AR at dischargeweremore likelymen and had a lower EuroSCORE than patients
with UC/Imp-AR. The severity of AR at discharge had a signiﬁcant impact on survival
(N/Tr, 84.6%; Mild, 78.2%; Mod/Sev, 70.9%; p¼0.02) with pairwise comparison
showing a signiﬁcant survival beneﬁt for patients with N/Tr vsMod/Sev AR (p¼0.005).
For 355 patients (UC/Imp-AR [n¼223], Worse-AR [n¼132]) with paired AR data at
baseline and discharge; UC/Imp-AR at discharge was associated with the best survival
(UC/Imp-AR, 83.5%; Worse-AR, 72.9%; p¼0.03). When combined, worsening and
severity of discharge AR inﬂuenced survival (UC/Imp to None/Tr/Mild 83.7%; UC/Imp
to Mod/Sev, 78.8%; Worse to Tr/Mild, 75.0%; Worse to Mod/Sev, 69.7% p¼0.07).
Pairwise comparisons showed the best survival in patients withUC/Imp-AR toNone/Tr/
Mild compared with Worse-AR to Mod/Sev, p¼0.007.
Conclusions: Severity and worsening of AR affected long-term survival. Survival was
most affected when AR worsened from baseline resulting in moderate/severe AR at
discharge. Final mild ARmay have an inﬂuence on late mortality especially if worsened
from baseline. These ﬁndings will help on the decisionmaking of the ﬁnal AR especially
when we expand the indications in the future to an intermediate risk cohort.
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Background: Transcatheter aortic valve implantation (TAVI) is considered in patients
with severe aortic stenosis who are not suitable or high risk for open surgery. Access
via the femoral approach is not feasible in people with extensive iliac and femoral
vascular disease and in these patients alternative routes of access – trans-apical,
subclavian or direct aortic are considered. We describe our early experience of a novel
approach for TAVI via the right common carotid artery.
Methods: We present a retrospective report of seven patients in whom access for
TAVI was precluded via both the femoral and subclavian arteries. A right common
carotid approach was successfully utilised in these patients.
Results: Seven patients underwent TAVI with CoreValve Revalving Systemª via the
carotid approach between August 2011 and April 2012. All these patients were
deemed unsuitable for the standard trans-femoral, subclavian or direct aortic
approaches. Mean age was 82 years. Procedure times ranged from 95-185 minutes.
Patients demographics are shown in Table 1. There were no peri-procedural neuro-
logical complications and mortality. Non of the patients required permanent
pacemaker implantation. One patient died on day 20 post-discharge related to haemo-
pericardium related to valve implantation.Patient
number Age Gender Euro score Prev CABG Prev MI EF < 40%
Renal
Impairment
1 84 Female 16 yes no no no
2 75 male 10 no yes yes no
3 71 female 10 yes no no no
4 85 female 12 no no no yes
5 85 female 15 no no no yes
6 89 female 15 no no no no
7 89 female 9 no no no yes
JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT AbstrConclusions: In this small series, the right common carotid route has been demon-
strated to be a feasible and safe access route for TAVI. It may represent a viable and
novel alternative to the femoral approach with the potential to expand the patient
group beneﬁting from this technology.
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Background: Although transcatheter aortic valve implantation (TAVI) is considered
less invasive compared to surgical aortic valve replacement, potential life-threatening
complications may occur. Bleeding complications are frequent and well respected, as
they might be associated with signiﬁcant impact on clinical outcomes. We investigated
the association between in-hospital bleeding events after TAVI using different deﬁ-
nitions and their respective impact on clinical outcomes.
Methods: Between August 2007 and April 2012, a total of 489 consecutive patients
with symptomatic severe aortic stenosis undergoing TAVI using different access
routes and devices were included into a prospective registry. Serious adverse events
were prospectively assessed and adjudicated according to standardized endpoint
deﬁnitions. Bleeding complications were adjudicated according to VARC 2 and for
the purpose of this analysis using the deﬁnitions of BARC, TIMI and GUSTO.
Results: Bleeding after TAVI was observed in 152 patients (31.1%) during the index
hospitalization and was mainly related to access site injury (66.4%). Life threatening
bleeding according to VARC 2 was associated with a signiﬁcant increase in mortality
at 30 days (HR 4.66, 95%CI 2.07-10.49) and 12 months of follow-up (HR 2.05, 95%
CI 1.17-3.57) as was BARC bleeding3 (HR 3.48, 95%CI 1.66-7.30 and HR 1.62,
95%CI 1.01-2.59, respectively), TIMI major (HR 4.52, 95%CI 1.96-10.46 and HR
2.05, 95%CI 1.16-3.62, respectively) and GUSTO severe or life-threatening bleeding
(HR 13.12, 95%CI 5.29-32.55 and HR 4.66, 95%CI 2.22-9.79, respectively).
Conclusions: Bleeding after TAVI was associated with a negative impact on
outcomes up to 12 months of follow-up, irrespective of bleeding deﬁnition. The
prognostic impact of bleeding according to the VARC 2 criteria was comparable with
other well–established bleeding deﬁnitions.TCT-781
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Background: Currently, pre-implant balloon aortic valvuloplasty (BAV) is consid-
ered a prerequisite for successful subsequent transapical transcatheter aortic valve
implantation (TA-AVI) using balloon-expandable devices. However, cerebral embo-
lization has been shown to originate at least in part from BAV procedures. Omitting
BAV may therefore reduce neurologic events after TAVI and facilitate the procedure
while yielding non-inferior hemodynamic and clinical outcomes.
Methods: From May, 2011 through December, 2012 a total of 50 consecutive patients
were treated by TA-AVI without pre-implant BAV (TA-AVI-BAV) using the
Edwards Sapien XT device (54% male, age 77.78.4 years, log EuroSCORE I
20.514.0%). Data were prospectively entered into a dedicated database, retrospec-
tively analyzed and compared to a consecutive series of conventional TA-AVI using
the same device (control group, n¼50).
Results: Overall device success rate was 92% (46/50) and 90% (45/50) in
TA-AVI-BAV and control groups respectively. Procedure time was similar in the
TA-AVI-BAV group compared to the control group (88.230.8 vs. 91.124.5
min, p¼0.60), while signiﬁcantly less contrast was used (137.667.8 vs.
182.978.1 ml, p<0.001). Postprocedural peak and mean transvalvular gradients
were 16.06.6 and 7.93.3 mmHg respectively in the TA-AVI-BAV group with
similar values in the control group (18.78.5 and 9.34.7 mmHg, p¼0.08 and
p¼0.09 respectively). Residual paravalvular leakage > grade 2 was present in 2%
and 8% in TA-AVI-BAV and control groups respectively (p¼0.36). Rates of 30-
day mortality and periprocedural stroke were 6% and 10% (p¼0.72) and 2% and
6% (p¼0.62) respectively.
Conclusions: TA-AVI-BAV is feasible and safe and has become our default tech-
nique for patients allocated to TA-AVI with balloon-expandable devices. This
approach resulted in less contrast agent used and facilitated the procedure without
compromising valve performance. Effects of TA-AVI-BAV on the incidence of
cerebrovascular events, other periprocedural complications or hemodynamic valve
performance need to be veriﬁed in larger patient numbers before general recom-
mendations can be made.acts/POSTER/Aortic Valve Disease and Treatment B237
